K‐ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos

We investigated point mutational activation of the ras genes (K‐ras codons 12, 13 and 61; N‐ras codons 12, 13 and 61; H‐ras codons 12 and 61) in primary, resected lung cancer by dot blotting and oligonucleotide hybridization. K‐ras mutations were found in 14 (29%) of the 48 lung tumour specimens examined, but no N‐ras or H‐ras mutations were found. The highest frequency of K‐ras mutation was observed in adenocarcinoma: 12 of the 21 samples studied (57%) had a mutation, which is one of the highest frequencies reported for lung adenocarcinoma. The commonest type of mutation in these lung tumour samples consisted of transversions: we observed 11, of which 8 (57% of all mutations) were G to T transversions. Most of the 48 patients studied had a history of heavy smoking, either with or without evidence of occupational exposure to asbestos. Statistical analysis revealed‐in addition to the highly significant association between the adenocarcinoma type of lung cancer and K‐ras mutation‐a clear association of K‐ras mutations with heavy life‐time smoking (≥50 pack‐years of cigarette smoking; odds ratio (OR) 4.9, 90% CI 1.2 ‐ 19.5, multivariate analysis). In addition, occupational asbestos exposure showed an elevated, but non‐significant, OR of 2.2 (90% CI 0.6 ‐ 8.7) with the presence of K‐ras mutation. We conclude that the occurrence of K‐ras mutations in adenocarcinoma of the lung is frequent, and that such mutations are associated with heavy life‐time exposure to tobacco smoke, possibly in combination with occupational exposure to asbestos fibres.

[1]  S. Anttila,et al.  Interaction between smoking and asbestos in human lung adenocarcinoma: role of K-ras mutations. , 1993, Environmental health perspectives.

[2]  S. Anttila,et al.  Asbestos exposure among Finnish lung cancer patients: occupational history and fiber concentration in lung tissue. , 1993, American journal of industrial medicine.

[3]  H. Vainio Mechanisms of Carcinogenesis in Risk Identification , 1992 .

[4]  H. Bartsch,et al.  An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. , 1992, Cancer research.

[5]  R. Metcalf,et al.  p53 and Kirsten-ras mutations in human mesothelioma cell lines. , 1992, Cancer research.

[6]  K. Hemminki,et al.  Serum oncoproteins and growth factors in asbestosis and silicosis patients , 1992, International journal of cancer.

[7]  R. Metcalf,et al.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners , 1992, The Lancet.

[8]  R. Ueda,et al.  p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. , 1992, Cancer research.

[9]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[10]  J. Lasky,et al.  The Pathobiology of Asbestos‐Induced Lung Disease: A Proposed Role for Macrophage‐Derived Growth Factors , 1991, Annals of the New York Academy of Sciences.

[11]  T. Lee,et al.  Role of Peptide Growth Factors in Asbestos‐Related Human Lung Cancer , 1991, Annals of the New York Academy of Sciences.

[12]  S. Jhanwar,et al.  Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. , 1991, Cancer research.

[13]  J. Minna,et al.  Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. , 1991, Oncogene.

[14]  S. Rodenhuis,et al.  Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.

[15]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[16]  R. Pero,et al.  Activated protooncogenes in human lung tumors from smokers. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[18]  M. Barbacid,et al.  ras oncogenes: their role in neoplasia , 1990, European journal of clinical investigation.

[19]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[20]  Marshall W. Anderson,et al.  Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[22]  P. Vineis,et al.  Estimates of the proportion of lung cancer attributable to occupational exposure. , 1988, Carcinogenesis.

[23]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[24]  R. L. Carter,et al.  IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans , 1980, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans.

[25]  E. C. Hammond,et al.  MORTALITY EXPERIENCE OF INSULATION WORKERS IN THE UNITED STATES AND CANADA, 1943‐1976 * , 1979, Annals of the New York Academy of Sciences.

[26]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[27]  J. Barrett,et al.  Possible cellular and molecular mechanisms for asbestos carcinogenicity. , 1992, American journal of industrial medicine.

[28]  J. Bos,et al.  A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides. , 1986, Gene.

[29]  Iarc Monographs,et al.  Cumulative Index to IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. , 1986, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans.

[30]  J. Aisner,et al.  Asbestos-related malignancy. , 1986, Critical reviews in oncology/hematology.